- Debt likely to be retired by 12/31/2009 or early 2010 at latest. - Reduced debt by 9.6 million since 1/1/2009 - Las Vegas lab to be fully operational by or before 1/31/2010. - 2010 looking to diversify revenue streams by obtaining contracts from other companies to store their stem cells and other biological products. - 2010 reducing costs of goods sold to increase revenue. - CEO points out that stock price has risen 4x with the dilution (since the beginning of this year), and that the debts are almost paid off which will likely end the dilution.
Main Points:
2009 Debt Reduction, Organic Growth, and acquisition
2010 Organic growth, acquisition, and diversification of revenue streams
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.